Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges

被引：33

作者：

Ye, Peng ^{[1
]}

Chi, Xiaoxia ^{[2
,3
]}

Cha, Jong-Ho ^{[1
]}

Luo, Shahang ^{[1
]}

Yang, Guanghui ^{[1
]}

Yan, Xiuwen ^{[1
]}

Yang, Wen-Hao ^{[1
,4
]}

机构：

[1] Guangzhou Med Univ, Key Lab Cell Homeostasis, Canc Res Guangdong Higher Educ Inst, Affiliated Canc Hosp & Inst, Guangzhou 910095, Peoples R China

[2] Inha Univ, Grad Sch, Dept Biomed Sci & Engn, Incheon 22212, South Korea

[3] Inha Univ, Dept Biomed Sci, Coll Med, Incheon 22212, South Korea

[4] China Med Univ, Grad Inst Biomed Sci, Taichung 406040, Taiwan

来源：

CELLS | 2021年 / 10卷 / 12期

基金：

中国国家自然科学基金; 新加坡国家研究基金会;

关键词：

E3 ubiquitin ligase; cancer immunotherapy; immune checkpoints; immune signaling pathway; NF-KAPPA-B; MHC CLASS-II; SMALL-MOLECULE INHIBITORS; TARGETED PROTEIN-DEGRADATION; APOPTOSIS IAP PROTEINS; DENDRITIC CELLS; T-CELLS; ANTIGEN PRESENTATION; CBL-B; SELECTIVE DEGRADATION;

D O I：

10.3390/cells10123309

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Cancer immunotherapies, including immune checkpoint inhibitors and immune pathway-targeted therapies, are promising clinical strategies for treating cancer. However, drug resistance and adverse reactions remain the main challenges for immunotherapy management. The future direction of immunotherapy is mainly to reduce side effects and improve the treatment response rate by finding new targets and new methods of combination therapy. Ubiquitination plays a crucial role in regulating the degradation of immune checkpoints and the activation of immune-related pathways. Some drugs that target E3 ubiquitin ligases have exhibited beneficial effects in preclinical and clinical antitumor treatments. In this review, we discuss mechanisms through which E3 ligases regulate tumor immune checkpoints and immune-related pathways as well as the opportunities and challenges for integrating E3 ligases targeting drugs into cancer immunotherapy.

引用

页数：34

共 50 条

[31] SIAH ubiquitin E3 ligases as modulators of inflammatory gene expression
Schmitz, Lienhard
Dreute, Jan
Pfisterer, Maximilian
Guenther, Stefan
Kracht, Michael
Chillappagari, Shashipavan
HELIYON, 2022, 8 (03)
[32] The Role of E3 Ubiquitin Ligases and Deubiquitinases in Inflammatory Bowel Disease: Friend or Foe?
Zou, Min
Zeng, Qi-Shan
Nie, Jiao
Yang, Jia-Hui
Luo, Zhen-Yi
Gan, Hua-Tian
FRONTIERS IN IMMUNOLOGY, 2021, 12
[33] The trafficking and regulation of membrane receptors by the RING-CH ubiquitin E3 ligases
Nathan, James A.
Lehner, Paul J.
EXPERIMENTAL CELL RESEARCH, 2009, 315 (09) : 1593 - 1600
[34] New insights on the function of SCF ubiquitin E3 ligases in the lung
Weathington, Nathaniel M.
Mallampalli, Rama K.
CELLULAR SIGNALLING, 2013, 25 (09) : 1792 - 1798
[35] E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma
Bielskiene, Kristina
Bagdoniene, Lida
Mozuraitiene, Julija
Kazbariene, Birute
Janulionis, Ernestas
MEDICINA-LITHUANIA, 2015, 51 (01): : 1 - 9
[36] Targeted modulation of E3 ligases using engineered ubiquitin variants
LeBlanc, Nicole
Mallette, Evan
Zhang, Wei
FEBS JOURNAL, 2021, 288 (07) : 2143 - 2165
[37] RING Finger E3 Ubiquitin Ligases: Structure and Drug Discovery
Chasapis, Christos T.
Spyroulias, Georgios A.
CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (31) : 3716 - 3731
[38] The E3 Ligases in Cervical Cancer and Endometrial Cancer
Zhai, Fengguang
Wang, Jie
Yang, Weili
Ye, Meng
Jin, Xiaofeng
CANCERS, 2022, 14 (21)
[39] Promising new therapeutic targets for regulation of inflammation and immunity: RING-type E3 ubiquitin ligases
Bulatov, Emil
Valiullina, Aygul
Sayarova, Regina
Rizvanov, Albert
IMMUNOLOGY LETTERS, 2018, 202 : 44 - 51
[40] E3 ubiquitin ligases Pellinos as regulators of pattern recognition receptor signaling and immune responses
Medvedev, Andrei E.
Murphy, Michael
Zhou, Hao
Li, Xiaoxia
IMMUNOLOGICAL REVIEWS, 2015, 266 (01) : 109 - 122

← 1 2 3 4 5 →